New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
10:55 EDTPFEEarnings Preview: Pfizer looks for earnings boost from Lyrica others
Pfizer (PFE) is scheduled to report first quarter earnings before the market open on Monday, May 5, with a conference call scheduled for 10:00 am ET. Pfizer, a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. EXPECTATIONS: Analysts are looking for earnings per share of 55c on revenue of $12.07B, according to First Call. The consensus range for EPS is 52c-59c on revenue of $11.82B-$12.86B. LAST QUARTER: Pfizer reported fourth quarter EPS of 56c, which beat consensus estimates of 52c, on revenue of $13.56B, which beat consensus estimates of $13.37B. In its Q4 earnings press release, Pfizer said reported revenues decreased $333M, or 2%, which reflected operational growth of $64M, or 1%, and the unfavorable impact of foreign exchange of $397M, or 3%. The operational increase was primarily due to the strong growth of Lyrica, Inlyta and Xalkori globally, Enbrel outside of North America, as well as Celebrex, Eliquis and Xeljanz, primarily in the U.S. Revenues were negatively impacted primarily by the expiration on October 31, of the collaboration agreement for Enbrel in North America, continued erosion for branded Lipitor in developed Europe and certain other developed markets. STREET RESEARCH: On April 29, Citigroup raised its price target on Pfizer to $36 from $31, citing its high conviction that the company will ultimately close an "extremely value enhancing" acquisition of AstraZeneca (AZN). Citi kept a Buy rating on the stock. PRICE ACTION: Shares of Pfizer are up over 3% since its last earnings report on January 28. In mid-morning trading ahead of Monday's earnings, shares of Pfizer are down over 1%.
News For PFE From The Last 14 Days
Check below for free stories on PFE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
16:00 EDTPFEOptions Update; September 19, 2014
Subscribe for More Information
10:07 EDTPFEHigh option volume stocks
Subscribe for More Information
September 17, 2014
07:43 EDTPFEBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
11:51 EDTPFEOECD looks to close tax loopholes with new proposals
Subscribe for More Information
07:19 EDTPFECompanies' share buybacks at fasttest clip since 2007, WSJ reports
Companies are buying back their own shares at its fastest pace since the financial crisis to fuel a stock rally, reports the Wall Street Journal. According to Birinyi Associates, companies have bought back $338.3B of stock in 1H14, the most since 2007. Citing an analysis by Barclays, companies with the largest buyback programs by dollar value have outperformed the broader market by 20% since 2008. Reference Link
September 15, 2014
09:25 EDTPFEJPMorgan biotech analysts hold an analyst/industry conference call
Analysts assess Pfizer's M&A options on an Analyst/Industry conference call to be held on September 15 at 10 am.
07:27 EDTPFEIBC Life Sciences to hold a conference
Subscribe for More Information
07:27 EDTPFEPfizer acquisition could drive shares higher, says JPMorgan
Subscribe for More Information
September 14, 2014
13:32 EDTPFEPfizer shares look cheap, Barron's says
Subscribe for More Information
September 12, 2014
10:32 EDTPFEPfizer CEO says company still open to inversion deal, FT says
Pfizer (PFE) CEO Ian Read said U.S. rhetoric against tax inversions has been "political theater" ahead of midterm elections and made clear that his company is still open to a potential tax-saving acquisition, according to Financial Times, which added Read's comment about not being “held hostage” over price would likely be read as a signal the company might look elsewhere after being rebuffed by AstraZeneca (AZN). The Fly notes that Bloomberg previously reported, citing people familiar with the matter, that Pfizer is looking at targets other than AstraZeneca, including Actavis (ACT). Shares of Actavis trading in New York are up 2% this morning. Reference Link
September 8, 2014
07:15 EDTPFEIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use